Lloyd Advisory Services’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$32.8K Sell
272
-684
-72% -$79K 0.01% 325
2025
Q4
$101K Buy
+956
New +$89.7K 0.04% 182
2024
Q2
Sell
-20,800
Closed -$2.74M 157
2024
Q1
$2.74M Buy
20,800
+17,051
+455% +$2.1M 0.59% 19
2023
Q4
$409K Sell
3,749
-10,482
-74% -$1.09M 0.19% 62
2023
Q3
$1.47M Buy
+14,231
New +$1.53M 0.48% 40
2022
Q3
Sell
-3,779
Closed -$344K 59
2022
Q2
$344K Sell
3,779
-614
-14% -$54.4K 0.27% 41
2022
Q1
$360K Buy
4,393
+1,127
+35% +$88.9K 0.17% 57
2021
Q4
$250K Sell
3,266
-320
-9% -$25.5K 0.12% 70
2021
Q3
$269K Sell
3,586
-104
-3% -$7.91K 0.14% 57
2021
Q2
$287K Buy
3,690
+1,260
+52% +$93.7K 0.15% 56
2021
Q1
$179K Sell
2,430
-215
-8% -$15.9K 0.1% 74
2020
Q4
$206K Buy
2,645
+631
+31% +$48.3K 0.11% 49
2020
Q3
$159K Buy
2,014
+51
+3% +$4K 0.1% 57
2020
Q2
$145K Buy
1,963
+374
+24% +$28.2K 0.09% 68
2020
Q1
$117K Buy
1,589
+1,109
+231% +$87.2K 0.09% 69
2019
Q4
$42K Buy
+480
New +$39.4K 0.04% 137

Other funds holding MRK

Lloyd Advisory Services's MRK Position: Q1 2026 in Review

Lloyd Advisory Services reduced its Merck (MRK) stake by 72% in Q1 2026, selling an estimated $79K and leaving 272 shares worth $32.8K. The position accounts for 0.01% of the portfolio, ranked #325.

Lloyd Advisory Services first reported a position in MRK in Q4 2019 and has held it in 16 quarters since. The position peaked at $2.74M in Q1 2024. 3,779 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Lloyd Advisory Services held 272 shares of Merck worth $32.8K as of Q1 2026.
  • Lloyd Advisory Services sold 684 Merck shares in Q1 2026, an estimated $79K.
  • Merck made up 0.01% of Lloyd Advisory Services's portfolio in Q1 2026, its #325 holding.
  • Lloyd Advisory Services first reported a position in Merck in Q4 2019 and has held it in 16 quarters since.
  • Lloyd Advisory Services's Merck position peaked at $2.74M in Q1 2024.
  • 3,779 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Lloyd Advisory Services's 13F filing for Q1 2026, filed 13 May 2026.